SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 198.02-1.4%Jan 26 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Henry Niman who wrote (10152)10/25/1997 11:15:00 PM
From: james  Read Replies (1) of 32384
 
I'm pretty late on this for sure

Thanks for pointing that out, Henry.

Their compounds on RXRs & PPAR are novel. But two things are also shall be ddressed:

1. These group of NHRs are highly heterogeneous, & their functions varies dramatically, mostly depends on other partners, & cellular context, & more and more are found. They seems to regulate many different gene expression. This will make the side-effects of this type of drugs unpredictable.

2. There are many natural ligands for RXR & PPAR in human body, & some of them exist in large quantity. It is hard to manipulate the physiological concentration of these drugs in local tissue, i.e., muscle & fat. And PPARs tend to be more active in fat than in muscle. Their agonists would redistribute more glucose into fat. That is a major no-no. Although there is some data in mice discounting this concern, I am not awared of any human data yet. Please inform me on that.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News